Impower150 added Atezolizumab to chemotherapy and Bevacizumab, significantly prolonging PFS and OS in metastatic non-squamous NSCLC patients, regardless of PD-L1 expression or EGFR/ALK status (28). This evidence concerns the gene ALK and non-small cell lung carcinoma.